Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine



   hereditary breast and ovarian cancer syndrome
  

Disease ID 1681
Disease hereditary breast and ovarian cancer syndrome
Definition
Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.
Synonym
familial breast and ovarian cancer syndrome
familial breast/ovarian cancer (brca1, brca2)
hboc syndrome
hboc syndromes
hereditary breast and ovarian cancer
hereditary breast and ovarian cancer syndrome (disorder)
hereditary breast and ovarian cancer syndrome [disease/finding]
hereditary breast/ovarian cancer (brca1, brca2)
syndrome, hboc
syndromes, hboc
Orphanet
UMLS
C0677776
MeSH
Comorbidity
UMLS | Disease | Sentences' Count(Total Sentences:4)
C0006142  |  breast cancer  |  1
C1140680  |  ovarian ca  |  1
C1140680  |  ovarian cancer  |  1
C0677886  |  epithelial ovarian cancer  |  1
Curated Gene
Entrez_id | Symbol | Resource(Total Genes:13)
11200  |  CHEK2  |  ORPHANET
5728  |  PTEN  |  ORPHANET
7157  |  TP53  |  ORPHANET
83990  |  BRIP1  |  ORPHANET
10111  |  RAD50  |  ORPHANET
5888  |  RAD51  |  ORPHANET
675  |  BRCA2  |  CLINVAR;CTD_human;ORPHANET
4683  |  NBN  |  ORPHANET
79728  |  PALB2  |  ORPHANET
5889  |  RAD51C  |  ORPHANET
672  |  BRCA1  |  CLINVAR;CTD_human;ORPHANET
580  |  BARD1  |  ORPHANET
5892  |  RAD51D  |  ORPHANET
Inferring Gene(Waiting for update.)
Text Mined Gene(Waiting for update.)
Locus
Symbol | Locus(Total Locus:14)
PTEN  |  10q23.31
CHEK2  |  22q12.1
RAD51C  |  17q22
RAD50  |  5q31.1
NBN  |  8q21.3
MRE11  |  11q21
TP53  |  17p13.1
BRCA1  |  17q21.31
BRCA2  |  13q13.1
PALB2  |  16p12.2
BARD1  |  2q35
RAD51  |  15q15.1
RAD51D  |  17q12
BRIP1  |  17q23.2
Disease ID 1681
Disease hereditary breast and ovarian cancer syndrome
Integrated Phenotype
HPO | Name(Total Integrated Phenotypes:7)
HP:0011027  |  Abnormality of the fallopian tube
HP:0012125  |  Prostate cancer
HP:0002894  |  Neoplasm of the pancreas
HP:0030406  |  Primary peritoneal carcinoma
HP:0003002  |  Breast carcinoma
HP:0100615  |  Ovarian neoplasm
HP:0002861  |  Melanoma
Text Mined Phenotype
HPO | Name | Sentences' Count(Total Phenotypes:1)
HP:0003002  |  Breast carcinoma  |  2
Disease ID 1681
Disease hereditary breast and ovarian cancer syndrome
Manually Symptom(Waiting for update.)
Text Mined Symptom(Waiting for update.)
Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)
Text Mining Genotype(Total Genotypes:0)
(Waiting for update.)
All Snps(Total Genotypes:237)
snpId pubmedId geneId geneSymbol diseaseId sourceId sentence score Year geneSymbol_dbSNP CHROMOSOME POS REF ALT
rs11571658NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340630TT-
rs12191266424884479672BRCA1umls:C0677776BeFreeMoreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.0.4199886542014TP53177670699CT,G,A
rs121912664248844797157TP53umls:C0677776BeFreeMoreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.0.1235287442014TP53177670699CT,G,A
rs1378529861993579783990BRIP1umls:C0677776BeFreeProtein truncating mutations in BRIP1 have been identified in hereditary breast and ovarian cancer families, and a recent report suggested that a recurrent truncating mutation (R798X) may have a role in PCa susceptibility.0.1205428842009BRIP11761716051GA
rs142899125NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332362582AG
rs273899695NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743104263T-
rs273900730NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743076579TAGAA
rs276174813NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332333272ATCTT-
rs276174918NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332380141AACATT
rs28897672NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743106487AT,G,C
rs28897686NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091783CT,A
rs28897696NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063903GT,A
rs28897743NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332346896GA,C,T
rs28897756NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332379913GA
rs386134270NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092695TACG
rs386833395NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA1;NBR21743124028CT-
rs387906563NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094706-CCACATGGCT,CCACATGGCTC,NNNNNNNNNN
rs397507322NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338413AAACG-
rs397507333NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338770AGAA-
rs397507389NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332357741GA,C
rs397507419NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332379893-A
rs397507907NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332355104CA-
rs397507922NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332356610GA,T
rs397507941NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332362573GA,C
rs397507954NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332363225AG
rs397507962NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332363273-TT
rs397509016NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092694AT-
rs39750903919865540672BRCA1umls:C0677776BeFreeThis report describes functional analysis of two BRCA1 missense mutations (Asp67Glu and Thr1051Ser) observed in the familial breast/ovarian cancer patients in Thailand.0.4199886542009BRCA11743092379GC
rs397509211NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743070923CT,A
rs397509231NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063871-A
rs397509326NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743115781TG,C
rs397515635NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332332667-NNNN,TTAG
rs398122622NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332398321G-
rs398122677NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091859G-
rs398122715NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332379401GT
rs41293455NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743082434GC,A
rs41293459NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063930CT,G,A
rs41293463NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743051071AT,C
rs41293497NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340037CA,G,T
rs41293511NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332363369GC
rs431825325NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339331-G
rs45553935NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743057122AG,C
rs45580035NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332380043CT
rs4987049NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332398437CG,T
rs55763607NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332370490CT
rs55770810NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063931GT,A
rs56253082NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340137GA,T
rs587780651NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338132T-
rs587780653NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332326250G-
rs587780659NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340917-A
rs587780798NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093025C-
rs587780802NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091657A-
rs587781487NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743099809-A
rs587781506NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332362594GA
rs61757642NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332394936AT
rs61764370206767563845KRASumls:C0677776BeFreeRecently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.0.0005428842011KRAS1225207290AC
rs62625307NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091933GA
rs62625308NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091924GC,A
rs730882134NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337702-TA
rs745456776NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338942-A,G
rs786204172NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339997AATC-
rs786204209NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339046-C
rs786204260NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094290-C
rs786204273NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332331011AA-
rs797044986NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337945-A
rs797044987NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339950ATC
rs79728106NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337521CA,T
rs80356866NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091690GA
rs80356888NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743104173GT,A
rs80356896NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063946CA
rs80356898NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093844GA
rs80356945NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093193GT,C,A
rs80356962NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743047666CT
rs80356969NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743049174GA
rs80356974NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063917AC
rs80356978NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092809CA
rs80356991NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743104136CT,A
rs80356992NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743074394GA
rs8035703319865540672BRCA1umls:C0677776BeFreeThis report describes functional analysis of two BRCA1 missense mutations (Asp67Glu and Thr1051Ser) observed in the familial breast/ovarian cancer patients in Thailand.0.4199886542009BRCA11743106467AC
rs80357055NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743049140GT
rs8035706424516540672BRCA1umls:C0677776BeFreeHere, we report the characterization of the BRCA1 c.190T>C (p.Cys64Arg) mutation, mapped to the RING-finger domain coding region, that we detected in 43 hereditary breast/ovarian cancer (HBOC) families, for the large part originating from the province of Bergamo (Northern Italy).0.4199886542013BRCA11743106478AG,C
rs80357082NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093496TA
rs80357115NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092597AC
rs80357123NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743057078GA
rs80357132NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063888AG
rs80357133NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743099817GA
rs80357233NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093393GC
rs80357251NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092896CT,A
rs80357292NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094569CT
rs80357382NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743106457TC
rs8035738219123044672BRCA1umls:C0677776BeFreeWe demonstrate that disruption of alternative transcript ratios is the mechanism causing hereditary breast/ovarian cancer associated with the BRCA1 R71G mutation.0.4199886542009BRCA11743106457TC
rs80357389NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743076488CT,A
rs80357433NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743071225GC
rs80357505NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094091-T
rs80357508NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091463TTGA-
rs80357509NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092046T-
rs80357516NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093653-NNNN,ACTA
rs80357522NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093570T-
rs80357567NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093647ACTG-
rs80357569NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094514-T
rs80357572NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743090963CT-
rs80357579NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091761TC-
rs80357580NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743067652GTTA-
rs80357590NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743049192G-
rs80357596NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092849TTTC-
rs80357598NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093088T-
rs80357601NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092529T-
rs80357604NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743104233-T
rs80357605NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092801TTGA-
rs80357609NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091827TTTAC-
rs80357629NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743045711-T
rs80357630NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093980A-
rs80357664NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093119CT-
rs80357669NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093074G-
rs80357685NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092804-T
rs80357688NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093460T-
rs80357701NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092199TGCT-
rs80357711NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091496T-
rs80357715NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093375-T
rs80357724NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094732AA-
rs80357729NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091903-T
rs80357797NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091859-NNNN,GGAA
rs80357801NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094084TAAT-
rs80357814NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093420TT-
rs80357819NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092664GATGA-
rs80357823NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743051075-G
rs80357824NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094846A-
rs80357832NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092722TATC-
rs80357842NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091672CACT-
rs80357856NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092478-NNNNN,TCTCA
rs80357859NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094327C-
rs80357867NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063350TTTC-
rs80357868NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091772AGAC-
rs80357877NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092040CTAGTATCTTC-
rs80357906NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743057065-G
rs80357915NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743074394-C
rs80357925NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743057070T-
rs80357928NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091769-AA
rs80357941NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094855A-
rs80357970NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743093056G-
rs80357971NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092849TT-
rs80357991NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743092532T-
rs80357997NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063889C-
rs80358015NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091432TC
rs80358023NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743070925CG
rs80358027NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743082403CT,G,A
rs80358033NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743095924TG,C
rs80358047NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743099773AT
rs80358061NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743104967AC
rs80358086NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743070922AG,C
rs80358094NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743063873CT,G,A
rs80358163NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743104968TC
rs80358178NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743091434CT
rs80358428NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332332889GT
rs80358435NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332319154GT
rs80358476NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332333333CT
rs80358515NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332319259CT
rs80358557NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337464CT
rs80358638NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338277GT
rs80358711NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339244CA,G
rs80358721NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339320CA,G
rs80358785NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340000CA,G
rs80358789NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340010CA
rs80358790NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340011CT
rs80358809NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332326563GA
rs80358814NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340212GT
rs80358815NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340219CA,G
rs80358851NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340479CT
rs80358998NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332331009CT
rs80359012NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332362585AG
rs80359082NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332370447GA
rs80359115NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332371043CT
rs80359133NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332379332GT
rs80359152NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332379800GA
rs80359200NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332394726CA,G
rs80359210NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332394808CT
rs80359212NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332394814CT
rs80359272NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332332735T-
rs80359283NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332332867AG-
rs80359303NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332333241ATAA-
rs80359304NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332333250TTTA-
rs80359306NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332333284-A
rs80359316NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332336284G-
rs80359351NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337161AAAC-
rs80359354NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337167GCAA-
rs80359357NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337191GA-
rs80359365NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337312-A,G
rs80359373NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337525AGAAA-
rs80359388NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337900TT-
rs80359391NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332337953TG-
rs80359395NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338035TG-
rs80359401NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338072A-
rs80359405NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338202GT-
rs80359439NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338637-T
rs80359444NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338753ACATT-
rs80359451NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338826CTGA-
rs80359452NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338827TGAA-
rs80359454NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338832GAAA-
rs80359461NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338986A-
rs80359462NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332338993T-
rs80359470NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339231AA-
rs80359475NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339320C-
rs80359480NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339428-A
rs80359489NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339513-T
rs80359507NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339705AA-
rs80359508NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339706-A
rs80359516NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339837AAATT-
rs80359520NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339930ATTA-
rs80359525NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332339971AGTAA-
rs80359530NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340073CT-
rs80359538NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340154CCAA-
rs80359541NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340183C-
rs80359550NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340301T-
rs80359584NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340757TAACT-
rs80359593NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340801TTAAA-
rs80359596NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340817TC-
rs80359604NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332329469GT-
rs80359605NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332340946TG-
rs80359636NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332354922CT-
rs80359645NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332330966TGAT-
rs80359659NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332330992ACAG-
rs80359671NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332331004CAAAT-
rs80359679NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332357886A-
rs80359705NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332363499C-
rs80359714NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332371001AG-
rs80359752NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332380142-A
rs80359754NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332394707ATTT-
rs80359773NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332398185-A
rs80359874NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743094317GATTCAGACTCCCCATCATGTGAGTCATCAGAACCTAACA-
rs80359876NA672BRCA1umls:C0677776CLINVARNA0.419988654NABRCA11743070932TCTTCTGGGGTCAGGCCAG-
rs81002797NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332326151GA,T
rs81002840NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332319330GA,C
rs81002843NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332356611TG
rs81002874NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332363178GC,T
rs81002885NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332316529TA,C
rs81002897NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332326614GA
rs81002899NA675BRCA2umls:C0677776CLINVARNA0.391215815NABRCA21332326615TC,G
GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)
GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)
Mapped by lexical matching(Total Items:2)
HP ID HP Name MP ID MP Name Annotation
HP:0003002Breast carcinomaMP:0010367increased spindle cell carcinoma incidencegreater than the expected number of a highly malignant variant of squamous cell carcinoma, occurring in a specific population in a given time period; spindle cell carcinoma shows biphasic proliferation of conventional SCC component and malignant spindle s
HP:0002894Neoplasm of the pancreasMP:0008261arrest of male meiosiscessation of the progression of the process of nuclear division that results in sperm with one half the normal chromosome number of the original cell
Mapped by homologous gene(Total Items:5)
HP ID HP Name MP ID MP Name Annotation
HP:0003002Breast carcinomaMP:0020039increased bone ossificationincrease in the formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone or a bony substance
HP:0002861MelanomaMP:0012431increased lymphoma incidencegreater than the expected number of neoplasms characterized by a proliferation of malignant lymphocytes in lymphoid tissue in a specific population in a given time period
HP:0002894Neoplasm of the pancreasMP:0014126increased mammary gland apoptosisincrease in the number of any cells of a mammary gland undergoing programmed cell death
HP:0012125Prostate cancerMP:0014126increased mammary gland apoptosisincrease in the number of any cells of a mammary gland undergoing programmed cell death
HP:0100615Ovarian neoplasmMP:0014126increased mammary gland apoptosisincrease in the number of any cells of a mammary gland undergoing programmed cell death
Disease ID 1681
Disease hereditary breast and ovarian cancer syndrome
Case(Waiting for update.)